Risk of hyperkalemia and combined use of spironolactone and long-term ACE inhibitor/angiotensin receptor blocker therapy in heart failure using real-life data: a population- and insurance-based cohort

Incidence, Predictors, and Outcomes Related to Hypo- and Hyperkalemia in Patients With Severe Heart Failure Treated With a Mineralocorticoid Receptor Antagonist

(2014) Orly Vardeny et al.   Circulation-Heart Failure

Effectiveness and Safety of Spironolactone for Systolic Heart Failure

(2013) Keane K. Lee et al.   AMERICAN JOURNAL OF CARDIOLOGY

Additional use of an aldosterone antagonist in patients with mild to moderate chronic heart failure: a systematic review and meta-analysis

(2012) Li-jun Hu et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms

(2012) Linda Shavit et al.   KIDNEY INTERNATIONAL

Frequency and Predictors of Hyperkalemia in Patients ≥60 Years of Age With Heart Failure Undergoing Intense Medical Therapy

(2011) Stefano Muzzarelli et al.   AMERICAN JOURNAL OF CARDIOLOGY

What is the risk of hyperkalaemia in heart failure?

(2011) Agata Bielecka-Dabrowa et al.   EXPERT OPINION ON PHARMACOTHERAPY

Epidemiology and risk profile of heart failure

(2010) Anh L. Bui et al.   Nature Reviews Cardiology

Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms

(2010) Faiez Zannad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Increasingly restrictive definitions of hyperkalemia outcomes in a database study: effect on incidence estimates

(2009) Marsha A. Raebel et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Serum Potassium and Clinical Outcomes in the Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)

(2008) Bertram Pitt et al.   CIRCULATION

Hyperkalemia Associated With Inhibitors of the Renin-Angiotensin-Aldosterone System

(2008) Akshay Desai   CIRCULATION